The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia

Bibliography

• Castelli WP, Garrison RJ, Wilson PW, Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;12:2835-8
   Google Scholar
• Tselepis AD, Dentan C, Karabina SA, PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995;15:1764-73
   PubMed Web of Science ®Google Scholar
• Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002;3:57-68
   PubMed Web of Science ®Google Scholar
• Thompson A, Gao P, Orfei L, Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010;375:1536-44
   PubMed Web of Science ®Google Scholar
• Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009;1791:327-38
   PubMed Web of Science ®Google Scholar
• Navab M, Berliner JA, Subbanagounder G, HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-8
   PubMed Web of Science ®Google Scholar
• Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J Hypertens 2000;18:655-73
   PubMed Web of Science ®Google Scholar
• Davies SS, Roberts LJ II. F(2)-isoprostanes as an indicator and risk factor for coronary heart disease. Free Radic Biol Med 2011;50:559-66
   PubMed Web of Science ®Google Scholar
• Ridker PM. C-reactive protein, inflammation, and cardiovascular disease: clinical update. Tex Heart Inst J 2005;32:384-6
   PubMed Web of Science ®Google Scholar
• Danesh J, Wheeler JG, Hirschfield GM, C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97
   PubMed Web of Science ®Google Scholar
• Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004;29:439-93
   PubMed Web of Science ®Google Scholar
• Mackness MI, Arrol S, Abbott C, Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35
   PubMed Web of Science ®Google Scholar
• Watson AD, Berliner JA, Hama SY, Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91
   PubMed Web of Science ®Google Scholar
• Petraki MP, Mantani PT, Tselepis AD. Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides. Curr Pharm Des 2009;15:3146-66
   Google Scholar
• Aviram M, Rosenblat M, Bisgaier CL, Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90
   PubMed Web of Science ®Google Scholar
• Durrington P. Dyslipidaemia. Lancet 2003;362:717-31
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Tsimihodimos V, Filippatos TD, High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia. Lipids 2011;46:521-8
   PubMed Web of Science ®Google Scholar
• Dounousi E, Papavasiliou E, Makedou A, Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006;48:752-60
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Karabina SA, Tambaki AP, Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002;22:306-11
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Kakafika A, Tambaki AP, Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003;44:927-34
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Koenig W, Christensen JH, The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr 2009;48:1-5
   Google Scholar
• Packard CJ, O'Reilly DS, Caslake MJ, Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000;343:1148-55
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H, Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-42
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Lowel H, Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004;110:1903-8
   PubMed Web of Science ®Google Scholar
• Oei HH, van der Meer IM, Hofman A, Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005;111:570-5
   PubMed Web of Science ®Google Scholar
• Brilakis ES, McConnell JP, Lennon RJ, Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 2005;26:137-44
   PubMed Web of Science ®Google Scholar
• Iribarren C, Gross MD, Darbinian JA, Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol 2005;25:216-21
   PubMed Web of Science ®Google Scholar
• Garza CA, Montori VM, McConnell JP, Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007;82:159-65
   PubMedGoogle Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN, The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-37
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 2004;109:1955-9
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Di Angelantonio E, Lowe G, C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82
   PubMed Web of Science ®Google Scholar
• Kostapanos MS, Milionis HJ, Elisaf MS. An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther 2008;13:157-74
   PubMed Web of Science ®Google Scholar
• Karalis IK, Bergheanu SC, Wolterbeek R, Effect of increasing doses of rosuvastatin and atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin 2010;26:2301-13
   PubMed Web of Science ®Google Scholar
• Belfort R, Berria R, Cornell J, Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. J Clin Endocrinol Metab 2010;95:829-36
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin 2009;25:1973-83
   PubMed Web of Science ®Google Scholar
• Krysiak R, Gdula-Dymek A, Okopien B. Monocyte-suppressing effect of bezafibrate but not omega-3 fatty acids in patients with isolated hypertriglyceridaemia. Basic Clin Pharmacol Toxicol 2011;109:23-9
   Google Scholar
• Zhao YT, Shao L, Teng LL, Effects of n-3 polyunsaturated fatty acid therapy on plasma inflammatory markers and N-terminal pro-brain natriuretic peptide in elderly patients with chronic heart failure. J Int Med Res 2009;37:1831-41
   Google Scholar
• Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000;28:505-13
   PubMed Web of Science ®Google Scholar
• Griffiths HR, Moller L, Bartosz G, Biomarkers. Mol Aspects Med 2002;23:101-208
   PubMed Web of Science ®Google Scholar
• Morrow JD, Hill KE, Burk RF, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990;87:9383-7
   PubMed Web of Science ®Google Scholar
• Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005;25:279-86
   PubMed Web of Science ®Google Scholar
• Lu TM, Ding YA, Leu HB, Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004;94:157-61
   PubMed Web of Science ®Google Scholar
• Dong Y, Steffen BT, Cao J, Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. Atherosclerosis 2011;214:422-5
   Google Scholar
• Ramezani M, Nazemian F, Shamsara J, Effect of omega 3 Fatty acids on plasma level of 8-isoprostane in kidney transplant patients. J Ren Nutr 2011;21:196-9
   Google Scholar
• Nalsen C, Vessby B, Berglund L, Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans. J Nutr 2006;136:1222-8
   PubMed Web of Science ®Google Scholar
• Dullaart RP, de Vries R, Voorbij HA, Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus. Eur J Clin Invest 2009;39:200-3
   Google Scholar
• Bergheanu SC, Van Tol A, Dallinga-Thie GM, Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007;23:2235–40
   PubMed Web of Science ®Google Scholar